JNJ Johnson & Johnson
- Official Name: JOHNSON & JOHNSON
- Headquarters: One Johnson & Johnson Plaza, NEW BRUNSWICK, NJ, 08933 US
- CEO: Joaquin Duato
- Website: jnj.com
- Key Investor: VANGUARD GROUP INC | 9.72%
- Dedicated Investor: ROBERT WOOD JOHNSON FOUNDATION | 87.12%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-16 | 1 | Won by 4.341 TOTW | 4.824 - 0.483 | ||
| 2025-07-23 | 2 | Won by 4.924 | 5.366 - 0.442 | ||
| 2025-07-29 | 2R | Won by 3.641 | 2.329 - (1.312) | ||
| 2025-07-30 | 3 | Lost by 0.842 | (2.105) - (1.263) | ||
| 2025-08-06 | 4 | Won by 3.762 | 1.963 - (1.799) | ||
| 2025-08-07 | 1R | Won by 3.007 | 0.614 - (2.393) | ||
| 2025-08-12 | 3R | Lost by 2.389 | (0.453) - 1.936 | ||
| 2025-08-13 | 5 | Won by 0.847 | 2.590 - 1.743 | ||
| 2025-08-20 | 6 | Won by 3.910 | 2.416 - (1.494) | ||
| 2025-08-21 | 2R | Won by 1.794 | 1.364 - (0.430) | ||
| 2025-08-27 | 7 | Won by 2.957 | (1.309) - (4.266) | ||
| 2025-09-03 | 8 | Won by 5.750 | 0.712 - (5.038) | ||
| 2025-09-04 | 3R | Won by 0.099 | 0.456 - 0.357 | ||
| 2025-09-10 | 9 | Lost by 2.623 | (1.256) - 1.367 | ||
| 2025-09-11 | 4R | Lost by 0.212 | 1.572 - 1.784 | ||
| 2025-09-17 | 10 | Won by 5.920 | 0.860 - (5.060) | ||
| 2025-09-17 | 1R | Won by 0.065 | 0.400 - 0.335 | ||
| 2025-09-24 | 11 | Lost by 1.104 | (0.291) - 0.813 | ||
| 2025-10-01 | 12 | Won by 4.348 TOTW | 5.285 - 0.937 | ||
| 2025-10-01 | QF | Won by 2.833 | 0.333 - (2.500) | ||
| 2025-10-08 | 13 | -- - -- | |||
| 2025-10-15 | 14 | -- - -- | |||
| 2025-10-22 | 15 | -- - -- |
Latest News
Yahoo - 2025-10-08
Johnson & Johnson (JNJ): A Cornerstone Among the Most Profitable Dividend Stocks
Johnson & Johnson (NYSE:JNJ) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) is one of...
Yahoo - 2025-10-07
Worried About a Recession? 2 Stocks to Buy Now to Prepare Your Portfolio
These two market leaders have increased their dividends for a combined 115 years.
Fintel - 2025-10-07
Citigroup Maintains Johnson & Johnson (JNJ) Buy Recommendation
Yahoo - 2025-10-07
LA County Jury Hits Johnson & Johnson with Nearly $1 Billion Verdict
LOS ANGELES, October 07, 2025--A Los Angeles County jury has returned damages totaling $966 million, including $950 million in punitive damages, to th...
Yahoo - 2025-10-07
Sector Update: Health Care Stocks Edge Down Late Afternoon
Health care stocks edged lower late Tuesday afternoon, with the NYSE Health Care Index and the Healt
Yahoo - 2025-10-07
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance
Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and n...
Yahoo - 2025-10-07
Prudential Financial (PRU): Assessing Valuation as Fundamental Challenges Draw Renewed Investor Scrutiny
Prudential Financial (PRU) has landed in the spotlight as investors take a closer look at its fundamentals. This follows news of shrinking net premium...
Yahoo - 2025-10-07
TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
Johnson & Johnson (NYSE: JNJ) today announced new 48-week data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) in...
Yahoo - 2025-10-07
Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class invest...
Yahoo - 2025-10-07
Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
Johnson & Johnson (NYSE: JNJ) – Johnson & Johnson*, a global leader in eye health, announced new data on the ACUVUE OASYS MAX 1-Day for ASTI...
Finnhub - 2025-10-07
J&J presents data highlighting superiority of its lenses for astigmatism
Johnson & Johnson announces new data demonstrating the superiority of its ACUVUE OASYS MAX 1-Day for Astigmatism lenses in terms of comfort and vi...
Yahoo - 2025-10-07
1 Reason I'm Watching Intuitive Surgical Stock in 2026
The surgical robotics pioneer could cement its leading position for years to come.
Yahoo - 2025-10-06
Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson
Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.
Fintel - 2025-10-06
Bernstein Maintains Johnson & Johnson (JNJ) Market Perform Recommendation
Yahoo - 2025-10-06
Earnings Are Coming. Wall Street Hopes Strong Profits Can Keep the Market Rally Going.
Third-quarter profit growth should be solid. Tech and AI will lead the way, but earnings momentum could broaden too.
Yahoo - 2025-10-06
Diffuse Cutaneous Systemic Sclerosis Market Forecast: Opportunities and Growth Trends Upto 2034 | DelveInsight
The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically ...
SeekingAlpha - 2025-10-06
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Many of the biotech stocks remain outside of Mr. Market's interest zone. Check out five biotech firms that may be of interest to Big Pharma playe...
Yahoo - 2025-10-06
How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results
JNJ's Innovative Medicine sales face biosimilar pressure and IRA headwinds, but growth drivers like Darzalex, Tremfya and Erleada may have ensure...
Yahoo - 2025-10-06
Did U.S. Orthopaedic Partners’ Medtech Deal Just Shift Johnson & Johnson’s (JNJ) Investment Narrative?
In the past week, U.S. Orthopaedic Partners announced a collaboration with Johnson & Johnson, selecting the medtech company as its official vendor...
Yahoo - 2025-10-06
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Yahoo - 2025-10-06
Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks
BOSTON, October 06, 2025--Basil Systems Launches Safety Signaling Solution to Proactively Detect and Prevent Medical Device Risks
Yahoo - 2025-10-04
Jim Cramer Believes Lawsuits Are No Longer a Major Threat to Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer put under the microscope. Cramer recalled his discussion with the company’s CEO, an...
SeekingAlpha - 2025-10-04
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Discover top Dow Dogs for dividend income. See why Verizon leads as a safe high-yield pick and find key strategies for safer Dow dividend investingâ...
Yahoo - 2025-10-03
Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $188.64, moving +1.43% from the previous trading session.
Yahoo - 2025-10-03
Stocks to Watch Recap: Apple, Applied Materials, Chevron, Broadcom
↗️ Apple (AAPL): Shares in the tech giant are trading near their all-time high from last December. Strong demand for new iPhone 17s have pushed Ap...
Yahoo - 2025-10-03
Sector Update: Health Care Stocks Gain Late Afternoon
Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health
Yahoo - 2025-10-03
Johnson & Johnson Stock Climbs As Wells Fargo Boosts Rating And Price Target
Johnson & Johnson Gets Wells Fargo Upgrade, Sends Shares Higher
Fintel - 2025-10-03
B of A Securities Maintains Johnson & Johnson (JNJ) Neutral Recommendation
Yahoo - 2025-10-03
Dow touches above 47,000, while J&J stock receives upgrade
Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including the Dow Jones Industr...
Yahoo - 2025-10-03
Wells Fargo sees ‘room to run’ for Johnson & Johnson, highlights pharma upside
Investing.com -- Wells Fargo upgraded Johnson & Johnson to Overweight from Equal Weight in a note on Friday, citing attractive valuation and great...
Show more
MarketWatch - 2025-10-03
UnitedHealth, Travelers share gains lead Dow's 325-point jump
Yahoo - 2025-10-03
Apple downgraded, Alibaba upgraded: Wall Street's top analyst calls
SeekingAlpha - 2025-10-03
ImmunityBio: A Small Bet Is Warranted
Fintel - 2025-10-03
Wells Fargo Upgrades Johnson & Johnson (JNJ)
MarketWatch - 2025-10-03
UnitedHealth, Caterpillar share gains lead Dow's 467-point rally
Yahoo - 2025-10-03
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery
Yahoo - 2025-10-02
Elon Musk Becomes First Person Worth $500 Billion, Tesla CEO's Wealth Is Now Larger Than Palantir, Alibaba
Yahoo - 2025-10-02
Boston Scientific aims for market leadership in electrophysiology
Yahoo - 2025-10-02
Johnson & Johnson (JNJ) Is Leading The Industry In Cancer Treatments, Says Jim Cramer
Yahoo - 2025-10-02
Johnson & Johnson (JNJ) Gains FDA Nod for TREMFYA Subcutaneous Therapy
Yahoo - 2025-10-01
Nanobiotix Says Early Trial Results Support JNJ-1900 With Chemoradiation in Esophageal Cancer
Yahoo - 2025-10-01
Drug Stock Rally Helps Push Dow and S&P 500 to Records
Yahoo - 2025-10-01
Marla Beck Steps Down as CEO of Hydrafacial Owner
Yahoo - 2025-10-01
Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End
Yahoo - 2025-10-01
ISRG Expands SP Indications: A Game Changer in Colorectal Surgery?
Yahoo - 2025-10-01
Bristol Myers, Takeda to pool data for AI-based drug discovery
Yahoo - 2025-10-01
Should You Buy Kenvue Stock After Its 30% Plunge?
Yahoo - 2025-09-30
Pfizer Stock Surges After Company Makes a Deal With President Trump
Yahoo - 2025-09-30
Drug Manufacturers Help Push US Equity Indexes Higher While Government Shutdown Looms
Yahoo - 2025-09-30
Stocks Post Late Rally After Trump Strikes Deal With Pfizer
SeekingAlpha - 2025-09-30
Regeneron: Growth Catalysts Incoming
Yahoo - 2025-09-30
Prudential Financial Elects Joseph Wolk to Board of Directors
Yahoo - 2025-09-30
Secure by Design, Not by Chance: Sicura Introduces a New Category of Cyber Defense at InfoSec World 2025
Yahoo - 2025-09-30
J&J gets FDA approval for Tremfya in paediatric psoriasis
Yahoo - 2025-09-30
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
Yahoo - 2025-09-30
Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus
Yahoo - 2025-09-29
The AI Rally Is on Pause. Try These 11 Non-Tech Stocks.
Yahoo - 2025-09-29
Johnson & Johnson (JNJ): A Dividend Aristocrat With Unmatched Stability
Yahoo - 2025-09-29
Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus
Yahoo - 2025-09-28
Why Johnson & Johnson Could Be the Ultimate Dividend King
Yahoo - 2025-09-28
Is There Still Room for Growth in J&J Shares After Recent FDA Approval?
SeekingAlpha - 2025-09-27
Best Dividend Aristocrats For October 2025
SeekingAlpha - 2025-09-27
IGA: Discount Continues To Narrow Helping Total Returns
Yahoo - 2025-09-27
Johnson & Johnson (JNJ) to Withdraw the LINC Reflux Management System from Markets Outside the U.S.
Yahoo - 2025-09-26
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
Yahoo - 2025-09-26
Trump's new tariffs on pharma, furniture, & trucks: What to know
Yahoo - 2025-09-26
Jim Cramer Discusses Kenvue Inc. (KVUE) & Legal Issues
Yahoo - 2025-09-26
What to Expect From Johnson & Johnson’s Q3 2025 Earnings Report
SeekingAlpha - 2025-09-26
President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio
MarketWatch - 2025-09-26
Boeing, IBM share gains lead Dow's nearly 150-point jump
MarketWatch - 2025-09-26
The Stock Market Is Up, but the Dollar Is Down. What It Means for You.
Yahoo - 2025-09-26
J&J: Still a Defensive Giant, or Too Dependent on Pharma?
Yahoo - 2025-09-26
Is pharma’s IRA pricing battle running out of steam?
Yahoo - 2025-09-26
Trump Plans New Tariff Push With 100% Rate on Patented Drugs
Yahoo - 2025-09-25
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Yahoo - 2025-09-25
AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold?
Yahoo - 2025-09-25
Johnson & Johnson (JNJ) Could Be a Great Choice
Yahoo - 2025-09-25
Josh Brown Talks About Johnson & Johnson’s (JNJ) Upcoming ‘Big Catalyst’
Yahoo - 2025-09-25
Hold These 5 ‘Forever Assets’ To Make Money in Your Sleep — Something Buffett Says Is a Must
Yahoo - 2025-09-25
Revision Skincare® Appoints Lisa Paley as CEO to Propel the Company’s Next Phase of Growth
Yahoo - 2025-09-25
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
SeekingAlpha - 2025-09-25
Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors
Yahoo - 2025-09-25
These 3 Dow Stocks Are Set to Soar in 2025 and Beyond
Yahoo - 2025-09-25
3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years
Yahoo - 2025-09-24
Why This Dividend King Still Stands Tall
SeekingAlpha - 2025-09-24
Takeda: Excellent Pipeline Kaizen - 6 Drugs, $20 Billion Annually
SeekingAlpha - 2025-09-24
Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Yahoo - 2025-09-24
As Trump Takes Aim at Tylenol, Should You Buy, Sell, or Hold Parent Company Kenvue Stock’s Here?
SeekingAlpha - 2025-09-24
Best Dividend Kings: September 2025
Yahoo - 2025-09-24
Tylenol maker Kenvue faces mounting crisis after Trump blast
Yahoo - 2025-09-24
Robotics and MedSurg Drive Stryker Growth Amid Margin Pressures
Yahoo - 2025-09-24
Climate Week NYC 2025 commences with slate of disaster response, green infrastructure deals
Yahoo - 2025-09-24
Johnson & Johnson (JNJ): Is the Current Valuation Justified After Recent Share Momentum?
Yahoo - 2025-09-23
J&J’s Abiomed starts third heart pump controller recall since June
Yahoo - 2025-09-23
Johnson & Johnson Impresses with Earnings Beat, Dividend Hike, and Bullish Analyst Target
Yahoo - 2025-09-23
Johnson & Johnson (JNJ) Gains FDA Nod for Subcutaneous Tremfya in Ulcerative Colitis
SeekingAlpha - 2025-09-23
Tracking John Paulson's Paulson & Company Portfolio - Q2 2025 Update
Yahoo - 2025-09-23
Kenvue stock rebounds as Trump's Tylenol claims face pushback
Yahoo - 2025-09-23
Sector Update: Health Care Stocks Advance Tuesday Afternoon
Fintel - 2025-09-23
Guggenheim Upgrades Johnson & Johnson (JNJ)
Yahoo - 2025-09-23
Tesla, Lululemon, Johnson & Johnson: Top analyst calls
Yahoo - 2025-09-23
Trethera Receives $1.8 Million NIH Grant to Advance TRE-515 Development for Crohn’s Disease
Yahoo - 2025-09-23
Johnson & Johnson, Boston Scientific to Headline MEDevice Boston 2025 Keynote Sessions
Yahoo - 2025-09-23
Nvidia Exposes a Stock Market Problem. How the Fed Can Solve It.
Yahoo - 2025-09-23
Tylenol-Maker’s Shares Sink amid Autism Scrutiny
Yahoo - 2025-09-23
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now
Yahoo - 2025-09-22
Kenvue Stock Hits All-Time Low, Turns Higher After-Hours
Yahoo - 2025-09-22
Johnson & Johnson (JNJ) Announced the European launch of Its Shockwave Javelin Peripheral IVL Catheter
Yahoo - 2025-09-22
Tylenol-maker Kenvue’s stock has lost a quarter of its value in 6 months as momentum grows for autism link despite repeated denials
Yahoo - 2025-09-22
J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?
Yahoo - 2025-09-22
Jim Cramer on Kenvue: “I Don’t Want to Dump it Right Here”
SeekingAlpha - 2025-09-21
Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q2 2025 Update
Yahoo - 2025-09-21
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?
Yahoo - 2025-09-21
Johnson & Johnson’s (JNJ) Dividend Growth Record Strengthens its Role in Dividend Paying Stocks
Yahoo - 2025-09-20
Is a Wave of FDA Successes Redefining the Innovation Story for Johnson & Johnson (JNJ)?
Yahoo - 2025-09-19
Sector Update: Health Care Stocks Mixed Late Afternoon
MarketWatch - 2025-09-19
Johnson & Johnson Gets Approval for Subcutaneous Induction Option for Ulcerative Colitis
Yahoo - 2025-09-19
J&J’s newly diagnosed multiple myeloma induction combo elicits 100% OR
Yahoo - 2025-09-19
Boost Your Portfolio With These Top-Ranked ETFs
Yahoo - 2025-09-19
Can MRK's New Drugs Drive Long-Term Growth Amid Looming Keytruda LOE?
Yahoo - 2025-09-19
Top Wide-Moat Stocks Worth a Look for Sustainable Growth
Finnhub - 2025-09-19
CHMP recommends approval of J&J's nipocalimab for myasthenia gravis
MarketWatch - 2025-09-19
Apple, Amgen share gains contribute to Dow's 118-point jump
Finnhub - 2025-09-19
J&J presents promising results in multiple myeloma
SeekingAlpha - 2025-09-19
AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy
Yahoo - 2025-09-19
Jim Cramer on Johnson & Johnson: “Very Rare Triple-A Balance Sheet”
Yahoo - 2025-09-18
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
Yahoo - 2025-09-18
J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why
SeekingAlpha - 2025-09-18
Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case
Yahoo - 2025-09-18
J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu
Yahoo - 2025-09-17
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Yahoo - 2025-09-17
Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)
Yahoo - 2025-09-17
GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years
Yahoo - 2025-09-17
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
Yahoo - 2025-09-17
Top Midday Stories: Markets Await Fed Rate Decision; China Regulator Reportedly Bans Nvidia Chip Sales to Alibaba, ByteDance
Yahoo - 2025-09-17
LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?
Yahoo - 2025-09-17
Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats
Yahoo - 2025-09-17
How Black Monday changed Wall Street forever
Finnhub - 2025-09-17
Johnson & Johnson announces positive results in psoriasis
MarketWatch - 2025-09-17
Johnson & Johnson's New Psoriasis Pill Outperforms in Phase 3 Trials
Yahoo - 2025-09-16
GSK Says It Will Spend $30B on U.S. Manufacturing and R&D
Yahoo - 2025-09-16
Guggenheim Reiterates a Hold on Johnson & Johnson (JNJ)
Yahoo - 2025-09-16
Johnson & Johnson (JNJ)’s Dividend Legacy: How a Healthcare Giant Built a Record of Consistent Dividends
Yahoo - 2025-09-16
Top 20 Companies Recognized in Labrador Transparency’s 2025 U.S. Transparency Awards
Yahoo - 2025-09-16
Insulet names new CFO; Dexcom CEO on leave
Yahoo - 2025-09-16
Medical device maker Insulet taps industry veteran Flavia Pease as CFO
Yahoo - 2025-09-16
Fosun's Henlius in talks with Johnson & Johnson, Roche on cancer drug
SeekingAlpha - 2025-09-15
How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse
Yahoo - 2025-09-15
ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?
Yahoo - 2025-09-15
Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
Yahoo - 2025-09-15
If You'd Invested $1,000 in Johnson & Johnson (JNJ) Stock 5 Years Ago, Here's How Much You'd Have Today
Yahoo - 2025-09-13
Jim Cramer Says Procter & Gamble Stock is “Still Way Too High”
Yahoo - 2025-09-12
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Yahoo - 2025-09-12
AbbVie Settles Rinvoq Patent Dispute: What It Means for the Stock
Yahoo - 2025-09-12
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
SeekingAlpha - 2025-09-12
What Looms Ahead After The Dow Jones Topped A Record Of 46,000
MarketWatch - 2025-09-12
Prescription Drug Ads Face Big Changes. These Stocks Could Get Hurt the Most.
Yahoo - 2025-09-12
Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors
Yahoo - 2025-09-11
Warren Buffett wouldn’t worry about cash if he retired with just $1M — here’s why and how to copy his strategy
Yahoo - 2025-09-11
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Yahoo - 2025-09-11
Johnson & Johnson seeks first European Medicines Agency approval for icotrokinra aiming to transform the plaque psoriasis treatment paradigm
Yahoo - 2025-09-11
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
Yahoo - 2025-09-10
Trump’s Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales.
Yahoo - 2025-09-10
Johnson & Johnson's FDA-Approved Bladder Cancer Drug Offers New Option For Patients Avoiding Surgery
Yahoo - 2025-09-10
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Yahoo - 2025-09-10
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
Yahoo - 2025-09-10
The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries
SeekingAlpha - 2025-09-10
Johnson & Johnson (JNJ) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Yahoo - 2025-09-10
Ion Platform Poised for Cost Optimization: A Margin Lever for ISRG?
Yahoo - 2025-09-10
MedtechWOMEN Announces Virginia L. Giddings as Winner of the 2025 Ferolyn Powell Award
SeekingAlpha - 2025-09-10
The Ultimate $1 Million All-Weather Portfolio For Lifetime Wealth
Yahoo - 2025-09-10
J&J obtains FDA approval for gemcitabine intravesical system
Yahoo - 2025-09-10
Jim Cramer on Johnson & Johnson: “Their Core Pharma Business is Roaring”
Yahoo - 2025-09-09
Tylenol maker’s stock lost billions after a rumor linking the medicine to autism. Wall Street says buy the dip as one bank sees a ‘major overreaction’
Yahoo - 2025-09-09
Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola
Yahoo - 2025-09-09
U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
SeekingAlpha - 2025-09-09
Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update
Yahoo - 2025-09-09
Are You Looking for a High-Growth Dividend Stock?
Yahoo - 2025-09-09
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
MarketWatch - 2025-09-09
Johnson & Johnson Gets FDA Approval for Bladder Cancer Treatment
Yahoo - 2025-09-09
Burq Makes Fast Company’s Seventh Annual List of the Best Workplaces for Innovators in Small and Mighty Companies: Fewer Than 100 Employees
Yahoo - 2025-09-09
Arkose Labs Debuts at No. 83 on Fast Company’s Seventh Annual List of the 100 Best Workplaces for Innovators
Yahoo - 2025-09-08
Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
Yahoo - 2025-09-08
A new class of sleep drugs draws Wall Street’s attention
Yahoo - 2025-09-08
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
Yahoo - 2025-09-08
Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus
Yahoo - 2025-09-08
Ronovo Surgical raises $67M, led by J&J venture arm
SeekingAlpha - 2025-09-08
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point
SeekingAlpha - 2025-09-08
Johnson & Johnson: All-Time Highs In Sight After Raised Guidance And A Technical Breakout
SeekingAlpha - 2025-09-08
Eli Lilly: Why Wall Street Still Loves Its GLP-1 Agonist Drugs
SeekingAlpha - 2025-09-08
Johnson & Johnson: A Safe Hold, But Lacking Catalysts To Beat The Market
SeekingAlpha - 2025-09-07
The BLSH Strategy: The Compounding Machine
Yahoo - 2025-09-06
3 Stocks to Buy and Hold Forever
Yahoo - 2025-09-06
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
SeekingAlpha - 2025-09-05
September Dogs Of The Dow Unleash One Ideal 'Safer' DiviDog
Yahoo - 2025-09-05
Kenvue Stock Tumbles on Report Kennedy Will Link Autism and Tylenol
Yahoo - 2025-09-05
Ronovo Surgical Closes Series D Financing
SeekingAlpha - 2025-09-05
Dividend Champion, Contender, And Challenger Highlights: Week Of September 7
Yahoo - 2025-09-05
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
MarketWatch - 2025-09-05